ClinicalTrials.gg
CompletedNCT02621905Updated Oct 26, 2018

Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg

A Phase 4 interventional study of Sporanox and Lozanoc in Neutropenia, sponsored by Mayne Pharma International Pty Ltd. Completed at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-26.

Sponsored by Mayne Pharma International Pty Ltd · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Neutropenia with a site in Australia — 1 open to participants now, 1 under way, 1 of them phase 3. Neutropenia · Australia.

Started
2015
with 1 other
Phase 4
Only one
of the 10
Registered
7th of 10
by date
Lead sponsor
2 of 10
Mayne Pharma International Pty Ltd

Among the 10 studies in Neutropenia with a site in Australia, this one is one of 2 that started in 2015, is the only one in phase 4, and was the 7th registered.

Neutropenia

316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.

Browse Neutropenia studies →

Open to participants now

1 of the 10 studies in Neutropenia with a site in Australia is open now. Recruiting first, the newest first:

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Neutropenia with a site in Australia, or all of them as a file.
02

Study summary

The pharmacokinetics of Sporanox and Lozanoc has not been compared in patients requiring anti-fungal prophylaxis or therapy. The present study is designed to compare the pharmacokinetics of Sporanox and Lozanoc in patients requiring primary prophylaxis. The 3-week exposure to each formulation is designed to allow for all participants to reach steady-state for each drug, as the time to steady-state can vary.

Read the detailed description

After confirmation of eligibility, participants will be randomly assigned 1:1 to commence therapy with either 100mg mane and 100mg nocte for 21 days or Sporanox 200mg mane and 200mg nocte with food for 21 days. If a subject enters the study already receiving itraconazole prophylaxis at a dose of itraconazole higher than 100 mg twice a day, the subject will then be dosed on study at the pre-study dosage; that is, the subject will take the same number of capsules per day on study as the subject was taking prior to enrolment in the study.

The following information will be collected at baseline; whether the participant is taking itraconazole prophylaxis and at what dose; whether the participant is taking gastric suppression therapy. Patients who are not taking food or who are taking gastric acid suppression therapy (antacids, an H2 antagonist or a proton pump inhibitor) can take Sporanox with cola or orange juice to maximise absorption as recommended in the Sporanox product label (not required for Lozanoc formulation).

At Day 22, participants assigned to

  • Lozanoc and who have completed 21 days of Lozanoc prophylaxis will cross over to the same number of Sporanox capsules with food for a further 21 days
  • Sporanox and who have completed 21 days of Sporanox prophylaxis will cross over to the same number of Lozanoc capsules for a further 21 days.

The dose of either drug may be dose-reduced or ceased for toxicity at the discretion of the investigator.

During the course of the treatment periods participants will undergo the following assessments:

  • Concurrent medication(s)
  • Clinical adverse events
  • Measurement of vital signs (weight, blood pressure, temperature)
  • Targeted physical examination
  • Documentation of any evidence of systemic fungal infection
  • Medication and meal diaries
  • 12-lead electrocardiogram (ECG)
  • Laboratory safety assessments: Renal function and electrolytes (urea, creatinine, estimated glomerular filtration rate [eGFR], sodium, potassium, chloride, bicarbonate), Liver function tests (bilirubin, albumin, total protein, alanine aminotransferase [ALT], aspartate aminotransferase [AST])
  • Pharmacokinetic testing: Trough (pre-morning dose; 0 hr) sample will be collected at Baseline (Day 1), and at Days 8, 15, 22, 29, 36 and 43. Post-dose samples will also be collected 2, 3.5 and 6 hours after the morning dose on Day 22 and Day 43
03

Conditions studied

  • Neutropenia

Browse trials for

Keywords

  • Prophylaxis
  • Steady-State
  • Bioavailability
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of written,
  • Age of at least 18 years
  • No clinical evidence of active systemic fungal infection
  • Physician-recommended primary prophylaxis against systemic fungal infections with itraconazole in patients who have had or about to have: a heart, lung or bone marrow transplant, combination chemotherapy for cancer; aspergilloma, chronic pulmonary aspergillus bronchitis, or allergic bronchopulmonary aspergillosis
  • Patients may be receiving itraconazole prophylaxis prior to entry into the study
  • between 15.0 and 35.0 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Pregnant, planning pregnancy or breastfeeding
  • Congestive cardiac failure or other causes of ventricular dysfunction that may outweigh the benefit of itraconazole
  • to either study drug or to any of their
  • Coadministration of the following drugs:

    • metabolised substrates that can prolong the -interval e.g., sertindole, terfenadine
    • CYP3A4 metabolised HMG-CoA reductase inhibitors e.g. simvastatin, lovastatin
    • Potent CYP3A4 inhibitors e.g. dronedarone
    • Triazolam, alprazolam and oral midazolam
    • Ergot alkaloids such as dihydroergotamine, ergometrine (ergonovine) and ergotamine
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    Sporanox

    100 mg

    Drug: Sporanox

  • Experimental
    Lozanoc

    50 mg

    Drug: Lozanoc

Interventions

  • At least 2 capsules twice a day for 3 weeks

    Also known as: itraconazole

  • At least 2 capsules twice a day for 3 weeks

    Also known as: itraconazole

06

What researchers measure

Primary outcomes

  1. Relative steady-state bioavailability

    Time frame: 3 weeks

07

Study locations

1 site
  • St Vincent's Hospital
    Darlinghurst, New South Wales 2010, Australia
08

References and documents

Individual participant data

Plan to share: No — Individual patient data will not be made available

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2015 to primary completion in Nov 2016, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2015
First posted
Dec 4, 2015
StartActual
Nov 2015
Primary completionActual
Nov 2016
CompletionActual
Dec 2016
Last update
Oct 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02621905
Lead sponsor
Mayne Pharma International Pty Ltd
Responsible party
Sponsor
First posted
Dec 4, 2015
Start date
Nov 2015
Primary completion
Nov 2016
Completion
Dec 2016
Last update
Oct 26, 2018

Study contacts

Deborah Marriott
principal investigator · St Vincent's Hospital, Sydney

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itraconazole

Start the discussion